Senores Pharmaceuticals Ltd Share Price

Pharmaceuticals - Indian - Formulations

NSE: SENORES Small Cap ISIN: INE0RB801010

As on 22 January 2025 at 18:41 IST

₹498.50

-11.65

(-2.28%)

Sell Buy

Over 1 Month

-8.42%

Over 6 Months

Over 1 Year

Over 3 Years

Senores Pharmaceuticals Ltd Summary

Close ₹ 498.50

Open ₹ 510

High ₹ 512.75

Low ₹ 490.05

Volume 2,87,355

Net Turnover (in ₹) ₹ 16,22,20,525.20

52Wk High ₹ 609.65

52Wk Low ₹ 435.25

52Wk High / Low

435.25

609.65

Senores Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 2,349.42

EPS (TTM) 0.18

Book Value (BV) 159.11

Div. Yield -

P/E (TTM) 2,836.94

Price/Book Value 3.21

Delivery % 34.21 %

Face Value 10

Key Ratios

PE Ratio -

PB Ratio -

EV to Sales -

PEG Ratio -

ROA 0.30

ROE 0.78

Debt-Equity 0.76

Net Profit Margin 2.38

Operating Profit Margin 19.94

Senores Pharmaceuticals Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	217.34	39.02	14.63	-	-
Total Expenses	192.40	26.58	13.49	-	-
Profit Before Tax	24.94	12.44	1.14	-	-
Profit After Tax	32.71	8.43	0.99	-	-
Operating Profit after Depreciation	34.39	14.57	1.71	-	-

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	314.74	53.65	14.61	-	-
Total Non Current Assets	370.97	79.72	32.10	-	-
Total Current Assets	250.91	51.34	27.05	-	-
TOTAL ASSETS	621.88	131.05	59.15	-	-
Total Shareholder's Fund	204.27	45.50	36.59	-	-

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	-19.87	-1.08	-10.45	-	-
Net Cash used in Investing Activities	-54.16	-48.29	-24.44	-	-
Net Cash used in Financing Activities	86.98	46.25	36.46	-	-

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	40.85	17.52	14.48	8.06	-
Total Expenses	38.82	14.93	13.65	7.66	-
Profit Before Tax	2.04	2.58	0.83	0.40	-
Profit After Tax	0.81	1.83	0.68	0.84	-
Operating Profit after Depreciation	4.75	4.58	1.39	0.60	-

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	27.68	4.36	4.76	4.41	-
Total Non Current Assets	245.90	83.33	41.19	6.76	-
Total Current Assets	39.96	19.30	13.98	8.20	-
TOTAL ASSETS	285.86	102.63	55.17	14.96	-
Total Shareholder's Fund	168.12	38.19	33.69	9.47	-

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	-62.82	-47.78	-24.06	-2.87	-
Net Cash used in Investing Activities	-13.51	1.07	-10.05	-4.37	-
Net Cash used in Financing Activities	86.68	45.33	33.88	8.50	-

No data available

Senores Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 499.87

S2 489.58

S3 474.97

Pivot 514.48

R1 524.77

R2 539.38

R3 549.67

Moving Average

20 SMA -

50 SMA -

100 SMA -

200 SMA -

Senores Pharmaceuticals Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

No available data

Senores Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Senores Pharmaceuticals Ltd	₹510.65	₹2,351.73
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

Senores Pharmaceuticals Ltd News

Senores Pharmaceuticals to conduct board meeting

On 23 January 2025

11 Jan 2025, 10:25 am

Senores Pharma gets final approval for Metoprolol Tartrate and Hydrochlorothiazide tablets

Senores Pharmaceuticals announced that it has received final approval from the United States Food and Drug Administration (USFDA) to market Metoprolol Tartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg.

10 Jan 2025, 10:49 am

Senores Pharmaceuticals receives USFDA approval for Metoprolol Tartrate and Hydrochlorothiazide Tablet

10 Jan 2025, 10:23 am

Senores Pharmaceuticals makes strong debut

Shares of Senores Pharmaceuticals were currently trading at Rs 576.75 at 10:24 IST on the BSE, representing a premium of 47.51% as compared with the issue price of Rs 391.

30 Dec 2024, 10:27 am

Senores Pharmaceuticals Ltd Stock Analysis

Annual revenue for Senores Pharmaceuticals Ltd increased by 133.24% to ₹40.85 crore in FY 2024 from ₹17.52 crore in FY 2023.
Annual Net Profit for Senores Pharmaceuticals Ltd decreased by 55.57% to ₹0.81 crore in FY 2024 from ₹1.83 crore in FY 2023.
Promoter Shareholding in Senores Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 45.76% in September 2024 to 45.76% in December 2024.
Senores Pharmaceuticals Ltd delivered a 1-year return of 0% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Senores Pharmaceuticals Ltd share price moved down by 2.28% from its previous close of INR ₹510.15. The latest Senores Pharmaceuticals Ltd share price is INR ₹498.50.
Senores Pharmaceuticals Ltd share price today has been at a low of 490.05 and a high of 512.75. Over the past 52 weeks, the Senores Pharmaceuticals Ltd share price has seen a low of 435.25 and a high of 609.65.